Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

TEVA-LIOTHYRONINE 25 MCG

LIOTHYRONINE (LIOTHYRONINE SODIUM) : 25 MCG · DIN 02494345 · TEVA CANADA LIMITED

Health Canada status: MARKETED

What is TEVA-LIOTHYRONINE?

TEVA-LIOTHYRONINE 25 MCG contains LIOTHYRONINE (LIOTHYRONINE SODIUM) : 25 MCG. It is listed in the Health Canada Drug Product Database under DIN 02494345, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Jul-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is TEVA-LIOTHYRONINE used for?

Hypothyroidism (replacement/supplemental therapy); Simple (non-toxic) goiter; T3 suppression test to differentiate hyperthyroidism from euthyroidism.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02494345
Brand nameTEVA-LIOTHYRONINE
Generic / active ingredientLIOTHYRONINE (LIOTHYRONINE SODIUM) : 25 MCG
ManufacturerTEVA CANADA LIMITED
Strength25 MCG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeH03AA02 LIOTHYRONINE SODIUM
AHFS class28:08.04.92
BiosimilarNo
Health Canada statusMARKETED
Status date10-Jul-2020
Original market date2021-03-22 00:00:00

How is it administered?

Oral. Hypothyroidism: Start 25 mcg daily, increase by 12.5-25 mcg every 1-2 weeks. Maintenance: 25-75 mcg daily. Myxedema/Elderly: Start 5 mcg daily. Titrate based on clinical response.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not explicitly detailed in provided text.

How is it supplied?

Not explicitly detailed in provided text (Supply section header present but content missing).

Contraindications

Hypersensitivity to liothyronine sodium; uncorrected adrenal insufficiency; acute myocardial infarction.

Warnings and precautions

Not for obesity/weight reduction (serious toxicity risk). Narrow therapeutic index. Use caution in patients with cardiovascular disorders (angina, ischemia) and the elderly.

What can be used instead?

Other Canadian products sharing ATC code H03AA02 LIOTHYRONINE SODIUM. 6 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
AURO-LIOTHYRONINE25 MCGTABLETAURO PHARMA INCMARKETEDDIN 02550008
AURO-LIOTHYRONINE5 MCGTABLETAURO PHARMA INCMARKETEDDIN 02549999
CYTOMEL25 MCGTABLETPFIZER CANADA ULCMARKETEDDIN 01919466
CYTOMEL5 MCGTabletPFIZER CANADA ULCMARKETEDDIN 01919458
TEVA-LIOTHYRONINE5 MCGTABLETTEVA CANADA LIMITEDMARKETEDDIN 02494337

Who else supplies LIOTHYRONINE SODIUM worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. LIOTHYRONINE SODIUM appears in 10 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for TEVA-LIOTHYRONINE

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02494345. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.